![]() |
Name |
(+)-(3R,4S)-4,5-Dihydroxymellein
|
Molecular Formula | C10H10O5 | |
IUPAC Name* |
4,5,8-trihydroxy-3-methyl-3,4-dihydroisochromen-1-one
|
|
SMILES |
CC1OC(=O)c2c(O)ccc(O)c2C1O
|
|
InChI |
InChI=1S/C10H10O5/c1-4-9(13)7-5(11)2-3-6(12)8(7)10(14)15-4/h2-4,9,11-13H,1H3/t4-,9-/m1/s1
|
|
InChIKey |
UKOUEEGEHXWHHO-ALFREKQPSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 210.19 | ALogp: | 0.7 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 87.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 15 | QED Weighted: | 0.441 |
Caco-2 Permeability: | -5.084 | MDCK Permeability: | 0.00000838 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.018 | 20% Bioavailability (F20%): | 0.008 |
30% Bioavailability (F30%): | 0.429 |
Blood-Brain-Barrier Penetration (BBB): | 0.405 | Plasma Protein Binding (PPB): | 77.49% |
Volume Distribution (VD): | 0.813 | Fu: | 30.48% |
CYP1A2-inhibitor: | 0.484 | CYP1A2-substrate: | 0.719 |
CYP2C19-inhibitor: | 0.058 | CYP2C19-substrate: | 0.15 |
CYP2C9-inhibitor: | 0.065 | CYP2C9-substrate: | 0.803 |
CYP2D6-inhibitor: | 0.27 | CYP2D6-substrate: | 0.281 |
CYP3A4-inhibitor: | 0.064 | CYP3A4-substrate: | 0.153 |
Clearance (CL): | 11.32 | Half-life (T1/2): | 0.82 |
hERG Blockers: | 0.007 | Human Hepatotoxicity (H-HT): | 0.105 |
Drug-inuced Liver Injury (DILI): | 0.703 | AMES Toxicity: | 0.249 |
Rat Oral Acute Toxicity: | 0.044 | Maximum Recommended Daily Dose: | 0.013 |
Skin Sensitization: | 0.141 | Carcinogencity: | 0.092 |
Eye Corrosion: | 0.006 | Eye Irritation: | 0.785 |
Respiratory Toxicity: | 0.156 |